Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis
- PMID: 21338316
- DOI: 10.1089/ars.2010.3792
Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis
Abstract
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) has been identified as a major receptor for oxidized low-density lipoprotein (ox-LDL) in endothelial cells, monocytes, platelets, cardiomyocytes, and vascular smooth muscle cells. Its expression is minimal under physiological conditions but can be induced under pathological conditions. The upregulation of LOX-1 by ox-LDL appears to be important for physiologic processes, such as endothelial cell proliferation, apoptosis, and endothelium remodeling. Pathophysiologic effects of ox-LDL in atherogenesis have also been firmly established, including endothelial cell dysfunction, smooth muscle cell growth and migration, monocyte transformation into macrophages, and finally platelet aggregation-seen in atherogenesis. Recent studies show a positive correlation between increased serum ox-LDL levels and an increased risk of colon, breast, and ovarian cancer. As in atherosclerosis, ox-LDL and its receptor LOX-1 activate the inflammatory pathway through nuclear factor-kappa B, leading to cell transformation. LOX-1 is important for maintaining the transformed state in developmentally diverse cancer cell lines and for tumor growth, suggesting a molecular connection between atherogenesis and tumorigenesis.
Similar articles
-
The role of LOX-1, a novel lectin-like receptor for oxidized low density lipoprotein, in atherosclerosis.Can J Cardiol. 2004 Aug;20 Suppl B:32B-36B. Can J Cardiol. 2004. PMID: 15309203 Review.
-
Oxidized LDL, LOX-1 and atherosclerosis.Cardiovasc Drugs Ther. 2011 Oct;25(5):419-29. doi: 10.1007/s10557-011-6341-5. Cardiovasc Drugs Ther. 2011. PMID: 21947818 Review.
-
Angiogenesis is a link between atherosclerosis and tumorigenesis: role of LOX-1.Cardiovasc Drugs Ther. 2011 Oct;25(5):461-8. doi: 10.1007/s10557-011-6343-3. Cardiovasc Drugs Ther. 2011. PMID: 21968594 Review.
-
Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy.Am J Med Sci. 2011 Aug;342(2):135-42. doi: 10.1097/MAJ.0b013e318224a147. Am J Med Sci. 2011. PMID: 21747278 Review.
-
Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders.Cardiovasc Res. 2006 Jan;69(1):36-45. doi: 10.1016/j.cardiores.2005.09.006. Epub 2005 Dec 1. Cardiovasc Res. 2006. PMID: 16324688 Review.
Cited by
-
circ_0003204 Regulates Cell Growth, Oxidative Stress, and Inflammation in ox-LDL-Induced Vascular Endothelial Cells via Regulating miR-942-5p/HDAC9 Axis.Front Cardiovasc Med. 2021 Apr 1;8:646832. doi: 10.3389/fcvm.2021.646832. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 33869307 Free PMC article.
-
LOX-1: Regulation, Signaling and Its Role in Atherosclerosis.Antioxidants (Basel). 2019 Jul 11;8(7):218. doi: 10.3390/antiox8070218. Antioxidants (Basel). 2019. PMID: 31336709 Free PMC article. Review.
-
Targeting LOX-1 Inhibits Colorectal Cancer Metastasis in an Animal Model.Front Oncol. 2019 Sep 19;9:927. doi: 10.3389/fonc.2019.00927. eCollection 2019. Front Oncol. 2019. PMID: 31608230 Free PMC article.
-
Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation.Front Cardiovasc Med. 2023 Mar 10;10:1148486. doi: 10.3389/fcvm.2023.1148486. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36970356 Free PMC article. Review.
-
Resveratrol protects against oxidized low‑density lipoprotein‑induced human umbilical vein endothelial cell apoptosis via inhibition of mitochondrial‑derived oxidative stress.Mol Med Rep. 2017 May;15(5):2457-2464. doi: 10.3892/mmr.2017.6304. Epub 2017 Mar 9. Mol Med Rep. 2017. PMID: 28447714 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials